Liz Burton, PhD (@liz_htx03) 's Twitter Profile
Liz Burton, PhD

@liz_htx03

Mom | Research | Taco enthusiast | Executive Director @MDAndersonNews - Views are my own.

ID: 1319460210176675841

calendar_today23-10-2020 02:06:50

66 Tweet

166 Takipçi

96 Takip Edilen

Paolo A. Ascierto (@pascierto) 's Twitter Profile Photo

At #BRIDGE23 Allison Betof Warner, MD, PhD overwhelms the audience with her energy … the eye of the tiger 💪🏻💪🏻💪🏻 I never want to debate with her … too risky 😅

At #BRIDGE23 <a href="/DrBetofMDPhD/">Allison Betof Warner, MD, PhD</a> overwhelms the audience with her energy … the eye of the tiger 💪🏻💪🏻💪🏻
I never want to debate with her … too risky 😅
Hussein Tawbi, MD, PhD (@htawbi_md) 's Twitter Profile Photo

Great permanent session on Neoadjuvant Therapy across malignancies Cancer Immunotherapy Bridge in Naples co- moderated by Paolo A. Ascierto Liz Burton, PhD amazing line up including Leisha Emmens, Tina Cascone Myriam Chalabi Neil D. Gross, MD, FACS Janis Taube Julie Stein Deutsch. Transforming SOC

Great permanent session on Neoadjuvant Therapy across malignancies <a href="/immunotherapy/">Cancer Immunotherapy</a> Bridge in Naples co- moderated by <a href="/PAscierto/">Paolo A. Ascierto</a> <a href="/Liz_htx03/">Liz Burton, PhD</a> amazing line up including Leisha Emmens, Tina Cascone <a href="/MyriamChalabi/">Myriam Chalabi</a> <a href="/DrNeilGross/">Neil D. Gross, MD, FACS</a> Janis Taube Julie Stein Deutsch. Transforming SOC
Allison Betof Warner, MD, PhD (@drbetofmdphd) 's Twitter Profile Photo

Neoadjuvant therapy is increasingly becoming SOC for #melanoma. Christian Blank proposing a modified paradigm for agent selection based on interferon signature- the main question- what do we use for IFN low? Triplet therapy seems very aggressive in this setting but IF tox is

Neoadjuvant therapy is increasingly becoming SOC for #melanoma. <a href="/ProfCUBlankNKI/">Christian Blank</a> proposing a modified paradigm for agent selection based on interferon signature- the main question- what do we use for IFN low? Triplet therapy seems very aggressive in this setting but IF tox is
Bella Glitza, MD, PhD (@glitzamdphd) 's Twitter Profile Photo

How to approach the treatment of patients with brain metastases? IMO in only one way- multidisciplinary care with a dedicated clinic, providing excellent patient care and a research platform! Hussein Tawbi, MD, PhD sharing the MD Anderson Cancer Center experience and success at #melanomabridge2023

How to approach the treatment of patients with brain metastases? IMO in only one way- multidisciplinary care with a dedicated clinic, providing excellent patient care and a research platform! <a href="/HTawbi_MD/">Hussein Tawbi, MD, PhD</a> sharing the <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> experience and success at #melanomabridge2023
Bella Glitza, MD, PhD (@glitzamdphd) 's Twitter Profile Photo

Dealing with Brain Metastases? Multidisciplinary care approach is a MUST! Hussein Tawbi, MD, PhD at MD Anderson Cancer Center is highlighting this important effort and its incredible impact on patient care (more than 1500 seen in our multidisciplinary Brain Mets clinic to date! ) #EADO2024

Dealing with Brain Metastases? Multidisciplinary care approach is a MUST! <a href="/HTawbi_MD/">Hussein Tawbi, MD, PhD</a> at <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> is highlighting this important effort and its incredible impact on patient care (more than 1500 seen in our multidisciplinary Brain Mets clinic to date! ) #EADO2024
OncoDaily (@oncodaily) 's Twitter Profile Photo

3P Solutions - The first edition of the I.N.N.O.V.A.T.E - Neoadjuvant immunotherapy across cancers 3PSolution Paolo A. Ascierto Christian Blank Liz Burton, PhD oncodaily.com/63471.html #Cancer #CancerResearch #HealthcareAdvancements #ImmunoTherapy #OncoDaily #Oncology

3P Solutions - The first edition of the I.N.N.O.V.A.T.E - Neoadjuvant immunotherapy across cancers
<a href="/3PSolution/">3PSolution</a> <a href="/PAscierto/">Paolo A. Ascierto</a> <a href="/ProfCUBlankNKI/">Christian Blank</a> <a href="/Liz_htx03/">Liz Burton, PhD</a>
oncodaily.com/63471.html 

#Cancer #CancerResearch #HealthcareAdvancements #ImmunoTherapy #OncoDaily #Oncology
Liz Burton, PhD (@liz_htx03) 's Twitter Profile Photo

Can’t imagine any other way to kick off #ASCO24! Incredible collaborations and multi disciplinary discussion today. Exciting things in melanoma and across cancers with neoadjuvant IO!

Professor Georgina Long AO (Bluesky @gvlongphdmd) (@profglongmia) 's Twitter Profile Photo

Inspiring discussion re; #neoadjuvant #melanoma with colleagues from International Neoadjuvant Melanoma Consortium (INMC). Massive positive impact on patient outcomes. Areas to refine - how much surgery is needed, who needs what #immunotherapy & for how long, does #pathology

Inspiring discussion re; #neoadjuvant #melanoma with colleagues from International Neoadjuvant Melanoma Consortium (INMC). Massive positive impact on patient outcomes. Areas to refine - how much surgery is needed, who needs what #immunotherapy &amp; for how long, does #pathology
Neil D. Gross, MD, FACS (@drneilgross) 's Twitter Profile Photo

The beauty of Napoli only to be outdone by the incredible scientific discussions pushing the frontiers of #neoadjuvant #immunotherapy across #Cancer at INNOVATE, hands down the best meeting of 2024 led by Liz Burton, PhD Paolo A. Ascierto Christian Blank!

The beauty of Napoli only to be outdone by the incredible scientific discussions pushing the frontiers of #neoadjuvant #immunotherapy across #Cancer at INNOVATE, hands down the best meeting of 2024 led by <a href="/Liz_htx03/">Liz Burton, PhD</a> <a href="/PAscierto/">Paolo A. Ascierto</a> <a href="/ProfCUBlankNKI/">Christian Blank</a>!
Neil D. Gross, MD, FACS (@drneilgross) 's Twitter Profile Photo

Great idea to add for future meeting. Work led by Maria Cabanillas, MD MD Anderson Cancer Center adding #neoadjuvant #immunotherapy to BRAF targeted therapy has shown great promise in anaplastic #thyroid #cancer!

Allison Betof Warner, MD, PhD (@drbetofmdphd) 's Twitter Profile Photo

Great start to #ESMO24 with the International Neoadjuvant Melanoma Consortium meeting. Liz Burton, PhD kicks us off showing us the progress in our field since the first meeting in 2016.

Great start to #ESMO24 with the International Neoadjuvant Melanoma Consortium meeting. <a href="/Liz_htx03/">Liz Burton, PhD</a> kicks us off showing us the progress in our field since the first meeting in 2016.
Hussein Tawbi, MD, PhD (@htawbi_md) 's Twitter Profile Photo

The International Neoadjuvant Melanoma Consortium (#INMC) meets for the 8th year running, so much progress & still much to consider, kicked off by Liz Burton, PhD providing context to multiple neoadjuvant trial results in melanoma & other cancers #ESMO24

The International Neoadjuvant Melanoma Consortium (#INMC) meets for the 8th year running, so much progress &amp; still much to consider, kicked off by <a href="/Liz_htx03/">Liz Burton, PhD</a> providing context to multiple neoadjuvant trial results in melanoma &amp; other cancers #ESMO24
Nature Medicine (@naturemedicine) 's Twitter Profile Photo

Out now for #ESMO24! In #ISPY2.2, neoadjuvant Dato-DXd, followed by sequential CT w/ or w/o targeted therapy & optional early resection after each therapy block in pts w/ high-risk #BreastCancer, was superior to SOC in a subgroup of pts. @DrLauraEsserman nature.com/articles/s4159…

Liz Burton, PhD (@liz_htx03) 's Twitter Profile Photo

What an honor to present some of my PhD work to amazing colleagues and friends at the Bridges meeting this week in Naples. Incredible group & brilliant scientists sharing insights and perspectives.